Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Basiliximab in
combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.